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Introduction
Colorectal adenocarcinoma is the third most common 
cancer and the third leading cause of cancer-related deaths 
in both men and woman. In 2011, there were 141,210 new 
cases of colorectal cancer and 49,380 colorectal cancer-
related deaths. It is estimated that a previous colorectal 
adenocarcinoma diagnosis was present in almost 1.2 million 
men and women living in the U.S. as of January 1, 2012, 
with 1- and 5-year relative survival rates of 83% and 
64%, respectively (1). One of the unique aspects of colon 
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cancer is that most arise from pre-malignant adenomas 
in an adenoma-carcinoma sequence. Initially, the colonic 
mucosa undergoes chromosomal mutations involving genes 
such as APC, k-ras and DCC, among others. The mucosa 
then proliferates into an adenoma and after additional 
mutations in genes such as p53, the adenoma transforms 
in a carcinoma (2). Since most colorectal cancers follow this 
adenoma-carcinoma time sequence, colonoscopy has become 
an intervention to detect and remove colorectal adenomas 
(CRA) before they become cancerous. While the use of 
screening tests prevention of colorectal cancer or detection 
and at an earlier stage is recommended, only 59% of men and 
women 50 years of age and older receive colorectal cancer 
screening according to published guidelines. Less than 40% 
of these cases are diagnosed at a local stage when treatment 
has a higher success rate. The benefits of early detection are 
documented in the medical literature. One study showed that 
colonic polypectomy through colonoscopy reduced colon 
cancer mortality by 53% (3).
In comparison to whites, all other racial and ethnic 
groups are less likely to be diagnosed with colorectal 
cancer at an early stage when treatment is more successful. 
Whether this discrepancy is due to true difference between 
these groups or is secondary to lack of access of care remains 
undetermined. Epidemiological studies that assess this 
discrepancy are crucial to determining the true nature of 
this racial disparity. According to the U.S. Census Bureau, 
Hispanics currently comprise 17% of the United States 
population at 53 million, and is projected to grow to 31% of 
the U.S. population by 2060 to an estimated 128.8 million 
people (4). In the US, Hispanics are the largest and fastest 
growing minority group. In the total Hispanic population, 
the incidence of colorectal cancer is 46.9 per 100,000 with a 
mortality of 15.3 per 100,000 (1). 
Aspirin and statins may both reduce the incidence 
of colorectal cancer (5). Although data on the inverse 
association of daily aspirin and statin therapy exists in white 
and black patients, scarce data exists on their effect on 
the incidence of CRA in the Hispanic patient population. 
In this study we assessed whether reported use of these 
medications was associated with the incidence of CRA in 
our multi-racial hospital. 
Methods
Patients
Following Institutional Review Board (IRB) approval at 
Nassau University Medical Center, a 530-bed tertiary 
care teaching hospital in East Meadow, New York, a 
retrospective chart review was performed between July 1, 
2009 and March 21, 2011. We established a database 
of 1,843 patients undergoing screening or diagnostic 
colonoscopy. Only patients with listed medications were 
used for analysis. Patients with colon cancer, inflammatory 
bowel disease, or incomplete colonoscopies were excluded 
from this study. A total of 1,495 patients were included in 
the analysis on statin use, 1,038 patients were included in 
the analysis on aspirin use and 672 patients were included 
in the analysis of use of both statin and aspirin. Data were 
collected on patient demographics and potential risk factors 
for adenoma including age, sex, race, body mass index 
(BMI), diabetes, hypertension, smoking, alcohol, and family 
history of colorectal cancer along with aspirin and/or statin 
use. Recorded colonoscopy findings included presence 
of adenoma, adenoma ≥10 mm, two or more adenomas, 
adenoma present in proximal colon, adenoma present in 
distal colon, largest adenoma in the proximal colon and 
largest adenoma in the distal colon.
Statistical analysis
Comparisons between categorical variables were made 
using a chi square test and a t-test was used for comparisons 
between continuous variables. Unconditional logistic 
regression was used to generate age-, gender-and race-
adjusted odds ratios and their 95% confidence intervals 
(CI) comparing medication users with non-users. Statistical 
analyses were performed with SAS 9.3 software. 
Results
Table 1 shows the demographic characteristics of statin users 
and non-users. The mean age was higher among statin 
users than non-users (59.6 vs. 54.4, P<0.0001). A larger 
proportion of the statin users (58.3%, n=229) vs. non-
users (48.1%, n=529) were female (P=0.0005). Users and 
non-users also differed in their racial breakdown (P=0.01), 
all metabolic and environmental factors including BMI 
(P<0.0001), presence of diabetes (P<0.0001), hypertension 
(P<0.0001), smoking status (P=0.03) and alcohol use 
(P=0.04). Statin users and non-users did not differ in 
their family history of colorectal cancer. Table 2 shows the 
association between statin use and colonoscopy findings, 
adjusted for age, sex, race, BMI, diabetes, hypertension and 
smoking or alcohol use. No associations were seen between 
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any of colonoscopy findings and use of statin in the total 
population or in Hispanics
Table 3 shows the demographic characteristics of aspirin 
users and non-users. The mean age was higher among 
aspirin users than non-users (60.0 vs. 54.9, P<0.0001). There 
was no significant difference between the groups in terms 
of gender breakdown. Users and non-users also differed in 
their racial breakdown (P<0.0001), BMI (P=0.002), presence 
of diabetes (P<0.0001) and hypertension (P<0.0001). 
Aspirin users and non-users did not differ in any other 
factors. Table 4 shows the association between aspirin 
use and colonoscopy findings, adjusted for age, sex, race, 
BMI, diabetes, hypertension and smoking or alcohol use. 
Compared to non-users of aspirin, those who used aspirin 
had an increased risk for having two or more adenomas [odds 
ratio (OR) =1.73, 95% CI: 1.00, 2.99, P=0.05] and presence 
of an adenoma in the proximal colon (OR =1.66, 95% CI: 
1.07, 2.58, P=0.02). No associations were seen between 
any other colonoscopy findings and aspirin use in the total 
population. There were no significant associations between 
aspirin use and colonoscopy findings in Hispanics.
Table 5 shows the demographic characteristics of statin 
Table 1 Demographics of statin users and non-users undergoing colonoscopy
Non statin user (n=1,102) Statin user (n=393) P value*
Age 54.4±14.9 59.6±9.6 <0.0001
Sex—female 529 (48.1%) 229 (58.3%) 0.0005
Race (%) 0.01
White 248 (22.5) 64 (16.3)
Black 380 (34.5) 153 (39.0)
Hispanic 429 (39.0) 149 (38.0)
Other 44 (4.0) 26 (6.6)
BMI 28.5±5.9 30.0±6.3 <0.0001
Diabetes—yes 165 (15.0%) 166 (42.2%) <0.0001
Hypertension—yes 472 (42.8%) 276 (70.2%) <0.0001
Smoking—yes 288 (26.1%) 81 (20.6%) 0.03
Alcohol—yes 209 (19.0%) 56 (14.3%) 0.04
Family history of colorectal cancer 82 (7.4%) 23 (5.9%) 0.48
*, t-test used for continuous variables and chi square test used for categorical variables. BMI, body mass index.
Table 2 Association between statin use and colonoscopy findings in total population and Hispanics
Total population Hispanics




Statin use vs. no 
use OR (95% CI)*
P value




Statin use vs. no 
use OR (95% CI)*
P value
Adenoma 216 (19.6) 82 (20.9) 1.01 (0.74, 1.38) 0.96 65 (15.2) 24 (16.1) 1.05 (0.60, 1.83) 0.87
Adenoma ≥10 mm 39 (3.5) 12 (3.1) 0.76 (0.37, 1.57) 0.46 10 (2.3) 2 (1.3) 0.59 (0.11, 3.27) 0.54
Two or more 
adenomas
67 (6.1) 34 (8.7) 1.32 (0.83, 2.10) 0.25 17 (4.0) 9 (6.0) 1.44 (0.57, 3.61) 0.44
Adenoma present 
in proximal colon
121 (11.0) 50 (12.7) 1.10 (0.75, 1.61) 0.63 28 (6.5) 11 (7.4) 1.14 (0.52, 2.52) 0.74
Adenoma present 
in distal colon
122 (11.1) 44 (11.2) 0.92 (0.62, 1.36) 0.66 42 (9.8) 18 (12.1) 1.26 (0.66, 2.40) 0.48
Largest adenoma 
in proximal colon
110 (10.0) 41 (10.4) 1.01 (0.67, 1.52) 0.96 25 (5.8) 9 (6.0) 0.95 (0.40, 2.25) 0.90
Largest adenoma 
in distal colon
114 (10.3) 42 (10.7) 0.96 (0.64, 1.44) 0.84 41 (9.6) 17 (11.4) 1.28 (0.67, 2.47) 0.45
*, adjusted for age, sex, race, BMI, diabetes, hypertension, alcohol and smoking. OR, odds ratios; CI, confidence intervals.
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and aspirin users and non-users. The mean age was higher 
among users of both medications than users of neither 
(61.2 vs. 54.1, P<0.0001). There was a difference between 
the groups in terms of gender breakdown (P=0.01), racial 
breakdown (P=0.04), BMI (P=0.002), presence of diabetes 
(P<0.0001) and hypertension (P<0.0001). Medication users 
and non-users did not differ in any other factors. Table 6 
shows the association between users of both medications 
and colonoscopy findings, adjusted for age, sex, race, 
BMI, diabetes, hypertension and smoking or alcohol use. 
Compared to non-users of either medication, those who used 
both had an increased risk for having two or more adenomas 
(OR =2.56, 95% CI: 1.21, 5.39, P=0.01). No associations 
were seen between any other colonoscopy findings 
and aspirin use in the total population. In the Hispanic 
population, compared to non-users of either medication, 
those who used both had an increased risk for having two 
or more adenomas (OR =19.04, 95% CI: 1.30, 280.09, 
P=0.03), adenoma present in the distal colon (OR =5.75, 95% 
CI: 1.64, 20.21, P=0.01) and largest adenoma in distal 
colon (OR =5.75, 95% CI: 1.64, 20.21, P=0.01). No other 
associations were seen in the Hispanic population.
Table 3 Demographics of aspirin users and non-users undergoing colonoscopy
Non aspirin user (n=731) Aspirin user (n=307) P value*
Age 54.9±10.8 60.0±9.3 <0.0001
Sex—female 367 (50.3%) 151 (49.2%) 0.73
Race (%)
White 202 (27.7) 61 (19.9)
<0.0001
Black 246 (33.7) 152 (49.7)
Hispanic 258 (35.3) 76 (24.8)
Other 24 (3.3) 17 (5.6)
BMI 28.6±5.9 29.8±6.2 0.002
Diabetes—yes 113 (15.5%) 130 (42.4%) <0.0001
Hypertension—yes 319 (43.6%) 231 (75.2%) <0.0001
Smoking—yes 197 (27.0%) 93 (30.3%) 0.27
Alcohol—yes 140 (19.2%) 55 (17.9%) 0.64
Family history of colorectal cancer 57 (7.8%) 21 (6.8%) 0.70
*, t-test used for continuous variables and chi square test used for categorical variables. BMI, body mass index.
Table 4 Association between aspirin use and colonoscopy findings in total population and Hispanics
Total population Hispanics
No aspirin  
use (n=731, %) 
Aspirin use  
(n=307, %) 
Aspirin use vs. no 
use OR (95% CI)*
P value
No aspirin  
use (n=258, %) 
Aspirin use  
(n=76, %) 
Aspirin use vs. no 
use OR (95% CI)*
P value
Adenoma 132 (18.1) 76 (24.8) 1.25 (0.87, 1.80) 0.23 34 (13.2) 13 (17.1) 1.56 (0.70, 3.50) 0.28
Adenoma ≥10 mm 17 (2.3) 15 (4.9) 2.03 (0.89, 4.62) 0.09 3 (1.2) 3 (4.0) 6.32 (0.62, 64.25) 0.12
Two or more 
adenomas
39 (5.3) 32 (10.4) 1.73 (1.00, 2.99) 0.05 8 (3.1) 6 (7.9) 2.91 (0.75, 11.24) 0.12
Adenoma present in 
proximal colon
68 (9.3) 51 (16.6) 1.66 (1.07, 2.58) 0.02 19 (7.4) 4 (5.3) 0.68 (0.20, 2.39) 0.55
Adenoma present in 
distal colon
80 (10.9) 38 (12.4) 0.92 (0.58, 1.47) 0.73 21 (8.1) 10 (13.2) 1.98 (0.78, 5.00) 0.15
Largest adenoma in 
proximal colon
59 (8.1) 41 (13.4) 1.55 (0.96, 2.50) 0.07 12 (4.7) 3 (4.0) 0.76 (0.17, 3.37) 0.72
Largest adenoma in 
distal colon
79 (10.8) 35 (11.4) 0.87 (0.54, 1.39) 0.56 22 (8.5) 11 (14.5) 2.23 (0.91, 5.51) 0.08
*, adjusted for age, sex, race, BMI, diabetes, hypertension, alcohol and smoking. OR, odds ratios; CI, confidence intervals.
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Discussion
To our knowledge this is the first study assessing aspirin and 
statin use in a Hispanic population. We found that statin use 
was not associated with any colonoscopy findings, though 
aspirin use increased the risk for two or more adenomas and 
adenoma in the proximal colon in our total population, but 
did not see the same results when restricting the analysis to 
Hispanics. An increased risk for two or more adenomas was 
also seen in the total population for users of both statins 
and aspirin. In Hispanics, use of both medications was 
associated with two or more adenomas, adenoma present in 
the distal colon and largest adenoma in distal colon.
There have been many trials discussing the relationship 
between aspirin/non-steroidal anti-inflammatory drugs 
(NSAIDs) and colorectal  adenoma/carcinomas in 
predominant white patient populations. One recent meta-
analysis combined four randomized double-blinded placebo 
trials that evaluated aspirin and prevention of CRA. The 
results showed that aspirin users had a pooled risk ratio of 
Table 5 Demographics of aspirin and statin users and non-users undergoing colonoscopy
Non aspirin and statin user (n=530) Aspirin and statin user (n=142) P value*
Age 54.1±11.3 61.2±9.5 <0.0001
Sex—female 244 (46.2%) 82 (57.8%) 0.01
Race (%)
White 156 (29.5) 30 (21.3)
0.04
Black 195 (36.9) 68 (48.2)
Hispanic 170 (32.1) 39 (27.7)
Other 8 (1.5) 4 (2.8)
BMI 28.4±6.0 31.3±6.5 <0.0001
Diabetes—yes 64 (12.1%) 71 (50.0%) <0.0001
Hypertension—yes 219 (41.3%) 118 (83.1%) <0.0001
Smoking—yes 155 (29.3%) 36 (25.4%) 0.36
Alcohol—yes 112 (21.1%) 23 (16.2%) 0.19
Family history of colorectal cancer 44 (8.3%) 13 (9.2%) 0.83
*, t-test used for continuous variables and chi square test used for categorical variables. BMI, body mass index.
Table 6 Association between aspirin and statin use and colonoscopy findings in total population and Hispanics
Total population Hispanics






OR (95% CI)* P value




(n=39, %) OR (95% CI)* P value
Adenoma 97 (18.3) 37 (26.1) 1.32 (0.79, 2.21) 0.29 23 (13.5) 9 (23.1) 2.55 (0.86, 7.60) 0.09
Adenoma ≥10 mm 15 (2.8) 6 (4.2) 0.95 (0.30, 3.00) 0.93 2 (1.2) 0 (0.0) N/A N/A
Two or more 
adenomas
26 (4.9) 19 (13.4) 2.56 (1.21, 5.39) 0.01 3 (1.8) 3 (7.7) 19.04 (1.30,280.09) 0.03
Adenoma present 
in proximal colon
48 (9.1) 25 (17.6) 1.74 (0.94, 3.23) 0.08 11 (6.5) 3 (7.7) 1.09 (0.20, 6.00) 0.92
Adenoma present 
in distal colon
58 (10.9) 20 (14.1) 1.13 (0.59, 2.14) 0.72 14 (8.2) 8 (20.5) 5.75 (1.64, 20.21) 0.01
Largest adenoma 
in proximal colon
46 (8.7) 19 (13.4) 1.27 (0.65, 2.49) 0.49 9 (5.3) 2 (5.1) 0.63 (0.08, 4.94) 0.66
Largest adenoma 
in distal colon
57 (10.8) 19 (13.4) 1.07 (0.56, 2.05) 0.84 14 (8.2) 8 (20.5) 5.75 (1.64, 20.21) 0.01
*, adjusted for age, sex, race, BMI, diabetes, hypertension, alcohol and smoking. OR, odds ratios; CI, confidence intervals; BMI, body mass index.
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0.83 (95% CI: 0.72, 0.96) for any adenoma, with an absolute 
risk reduction of 6.7% compared to placebo (6). They 
concluded that aspirin is effective for the prevention of 
CRA in patients with a history of these lesions. There have 
also been studies looking specifically at NSAIDS and colon 
cancer. Patients taking 200mg BID of Celecoxib had a 
reduced rate of sporadic CRA (RR: 0.67, 95% CI: 0.59, 0.77), 
while those taking 400 mg BID also had a reduced risk 
of sporadic CRA (RR: 0.55, 95% CI: 0.48, 0.64) (7). 
Unfortunately, there are limited randomized trials looking 
at non-COX-2 selective NSAIDS. One study showed that 
the NSAID, sulindac, reduced the risk of polyp formation 
in patients with familial adenomatous polyposis (8). 
There are some trials showing that aspirin did not reduce 
the incidence of colon cancer and none demonstrating 
an association with the presence of adenomas. One study 
showed that alternate day 100 mg aspirin did not reduce 
the risk of colon cancer (9), while another trial revealed that 
aspirin given for five years of duration did not reduce the 
risk of colon cancer (10). It is theorized that these trials did 
not show risk reduction because of low doses of ASA (11). 
Though it is theorized that the mechanism stems from 
aspirin/NSAIDs ability to block COX-2 enzymes, which 
are expressed in the majority of colonic adenomas and 
not in normal colonic tissue, it should be noted that the 
mechanism of colon cancer prevention through aspirin/
NSAIDs use is unclear (12). 
There have also been many studies looking at the 
relationship between statins and colorectal cancer risk. 
One case-control study showed that statin use for five years 
was associated with a 47 percent relative risk reduction of 
colorectal cancer (13). The proposed anti-tumor mechanism 
of statins is likely due to a pleiotropic effect on cells. Statins 
inhibit HMG-CoA reductase, decreasing cellular levels of 
melvonate and result in cells unable to generate products 
involved in cell functioning. Statins have also been shown 
to induce apoptosis in tumor cells (14). Despite these 
findings and proposed mechanism for protection, there are 
several studies showing no reduction of colorectal cancer 
risk. A meta-analysis including random controlled trials, 
cohort, and case control studies with more than 1.5 million 
participants, showed no association with statin use and risk 
of colorectal cancer. However, sub-group analysis of just 
case control studies did show a modest reduction in the risk 
of colon cancer (RR: 0.91; 95% CI: 0.87, 0.96) (15). 
Statins have also been reported to increase the risk of 
adenoma formation with a large prospective randomized 
trial demonstrating that statin use increased the risk of 
adenoma formation. However, this was not found among 
patients also taking Celebrex, and it was suggested that 
the significant antitumor effect Celebrex produces seemed 
to counteract the tumor-promoting effect of statins. The 
results overall showed that statin use for greater than three 
years showed a 40% increase in adenoma detection during 
five years of surveillance (RR: 1.39 95% CI: 1.04, 1.86) (16). 
Though our study showed increased colonoscopy 
findings with statin use, there were several limitations to 
the study. Limitations of our study include a retrospective 
design and small sample size, particularly in the analysis 
looking at combined medication use in Hispanics. Some 
of the OR CIs were wide, most likely due to sample size 
limitations. Additionally, a further description of Hispanic 
immigration also was not defined in our study and Hispanics 
can be represented by a diverse ethnic population. There is 
always a possibility of selection bias, and that the patients 
studied were a population preselected to develop adenomas 
while on statins. Another weakness to our study is that 
the type of statin used was unknown, as the type of statin 
may influence tissue response. Lipophilic statins are more 
likely to achieve higher drug levels in nonhepatic tissues, 
thus being more likely to alter the biology of colorectal 
mucosa than hydrophilic statins (16). Strengths include 
a diverse patient population sample representative of the 
actual growing US population. Additionally, our analysis 
controlled for multiple confounding data that could 
influence adenoma detection.
In summary, we have determined that combined aspirin 
and statin use, along with the sole use of aspirin, does not 
protect against CRA and was associated with their presence 
in the Hispanic population. It is unclear why combined 
use of aspirin and statin medications was associated with 
colonoscopy findings in Hispanics. Our findings may be due 
to environmental factors such as dietary, colonic flora, or 
genetic susceptibility. Overall, we have demonstrated there 
is an association with the presence of CRA and aspirin/
statin use, and our results support further investigation of 
this finding in the Hispanic population. 
Acknowledgements
Disclosure: The authors declare no conflict of interest.
References
1. American Cancer Society. Cancer Treatment and 
Survivorship Facts & Figures 2012-2013. Atlanta: 
118 Davis-Yadley et al. Colorectal adenomas with aspirin and statins 
© Pioneer Bioscience Publishing Company. All rights reserved. J Gastrointest Oncol 2014;5(2):112-118www.thejgo.org
American Cancer Society, 2012. 
2. Cho KR, Vogelstein B. Genetic alterations in the 
adenoma--carcinoma sequence. Cancer 1992;70:1727-31.
3. Zauber AG, Winawer SJ, O’Brien MJ, et al. Colonoscopic 
polypectomy and long-term prevention of colorectal-
cancer deaths. N Engl J Med 2012;366:687-96.
4. United States Census Bureau. Profile America Facts for 
Features. 30 July, 2013. Available online: www.census.gov/
newsroom/releases/archives/facts_for_features_special_
editions/cb13-ff19.html
5. Mansouri D, McMillan DC, Roxburgh CS, et al. The 
impact of aspirin, statins and ACE-inhibitors on the 
presentation of colorectal neoplasia in a colorectal cancer 
screening programme. Br J Cancer 2013;109:249-56.
6. Cole BF, Logan RF, Halabi S, et al. Aspirin for the 
chemoprevention of colorectal adenomas: meta-analysis of 
the randomized trials. J Natl Cancer Inst 2009;101:256-66. 
7. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib 
for the prevention of sporadic colorectal adenomas. N 
Engl J Med 2006;355:873-84.
8. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment 
of colonic and rectal adenomas with sulindac in familial 
adenomatous polyposis. N Engl J Med 1993;328:1313-6.
9. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in 
the primary prevention of cancer: the Women’s Health Study: 
a randomized controlled trial. JAMA 2005;294:47-55.
10. Gann PH, Manson JE, Glynn RJ, et al. Low-dose aspirin 
and incidence of colorectal tumors in a randomized trial. J 
Natl Cancer Inst 1993;85:1220-4.
11. Dubé C, Rostom A, Lewin G, et al. The use of aspirin 
for primary prevention of colorectal cancer: a systematic 
review prepared for the U.S. Preventive Services Task 
Force. Ann Intern Med 2007;146:365-75.
12. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of 
colorectal cancer in relation to the expression of COX-2. 
N Engl J Med 2007;356:2131-42.
13. Poynter JN, Gruber SB, Higgins PD, et al. Statins and the 
risk of colorectal cancer. N Engl J Med 2005;352:2184-92.
14. Boudreau DM, Yu O, Johnson J. Statin use and cancer 
risk: a comprehensive review. Expert Opin Drug Saf 
2010;9:603-21. 
15. Bonovas S, Filioussi K, Flordellis CS, et al. Statins and 
the risk of colorectal cancer: a meta-analysis of 18 studies 
involving more than 1.5 million patients. J Clin Oncol 
2007;25:3462-8.
16. Bertagnolli MM, Hsu M, Hawk ET, et al. Statin use 
and colorectal adenoma risk: results from the adenoma 
prevention with celecoxib trial. Cancer Prev Res (Phila) 
2010;3:588-96.
Cite this article as: Davis-Yadley AH, Lipka S, Shen H, 
Shah H, Swarup S, Barnowsky A, Silpe J, Mosdale J, Pan 
Q, Fridlyand S, Sreeharshan S, Abraham A, Viswanathan P, 
Krishnamachari B. Ethnic disparities in the risk of colorectal 
adenomas associated with aspirin and statin use: a retrospective 
multiethnic study. J Gastrointest Oncol 2014;5(2):112-118. doi: 
10.3978/j.issn.2078-6891.2014.010
